Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Lucretius who wrote (241738)	5/20/2003 3:26:50 PM
From: yard_man	Read Replies (1) \| Respond to of 436258

I said bottom today -- you got to buy them at the bottom -- going to send you back to school with WFG. He'll whip you into shape, pronto -- with or without your spandex.

To: Lucretius who wrote (241738)	5/20/2003 3:29:52 PM
From: MythMan	Read Replies (3) \| Respond to of 436258

RealCommentary from TheStreet.com Drugs Are Taking an Unfair Beating Tuesday May 20, 3:22 pm ET By James J. Cramer, Drug stocks have just been pummeled here, trashed into oblivion. To me, that's a mistake. These are companies that, for the most part, are huge weak-dollar beneficiaries that aren't really about to feel any squeeze from the Maine plan. I own Pfizer (NYSE:PFE - News) and Schering-Plough (NYSE:SGP - News). That's a typical strategy of mine: owning the best and the worst. I am confident that Pfizer will generate huge cash, pay big dividends over time and buy back lots of stock, although I wish they would just raise the dividend. Schering-Plough is a play on a turnaround, Fred Hassan being the smartest fix-up guy in the land.